SOPH
SOPHiA GENETICS SA
$8.65
+3.84%
2026-08-21
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Key Fundamentals
Forward P/E
-15.00
EPS (TTM)
$-1.16
ROE
-101.2%
Revenue Growth (YoY)
27.2%
Profit Margin
-93.9%
Debt/Equity
74.39
Price/Book
7.68
Beta
0.92
Market Cap
$638.5M
Avg Volume (10D)
570K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$8.68
60D Low
$4.70
Avg Volume
365K
Latest Close
$8.65
Get breakout alerts for SOPH
Sign up for Breakout Scanner to receive daily notifications when SOPH triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
SOPHiA GENETICS SA (SOPH) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SOPH daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SOPH operates in the Healthcare sector within the Health Information Services industry. Data is provided for informational purposes only and does not constitute financial advice.